Acquiring Company
Celltrion
Acquired Company
iQone Healthcare Switzerland
Incheon
VersoixManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CarePharmaceuticalDescription
Celltrion, a global biopharmaceutical leader, has announced the acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. This acquisition represents a significant milestone in Celltrion’s European expansion strategy, providing access to in-licensing opportunities and further strengthening its pipeline of innovative therapies.
Quick answer
Celltrion is acquiring iQone Healthcare Switzerland, announced November 14, 2024. Celltrion is based in Incheon, Seoul, South Korea.
- How much did Celltrion pay for iQone Healthcare Switzerland?
- The deal value was not disclosed.
- What does Celltrion do?
- Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives..
- Where are Celltrion and iQone Healthcare Switzerland based?
- Celltrion is based in Incheon, Seoul, South Korea. iQone Healthcare Switzerland is based in Versoix, Geneva, Switzerland.
- Who are the decision-makers at Celltrion?
- Fundz holds 4 contacts at Celltrion. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie completes acquisition of Aliada Therapeutics to enhance neuroscience development (December 11, 2024)
- AbbVie announces acquisition of Aliada Therapeutics, focusing on Alzheimer's disease and neuroscience pipeline (October 28, 2024)
- Boston Scientific completes acquisition of Axonics, Inc. to expand into sacral neuromodulation (November 15, 2024)
- Merck completes acquisition of investigational B-Cell depletion therapy, CN201, from Curon Biopharmaceutical (October 1, 2024)
- Novo Holdings completes acquisition of Catalent, Inc. (December 18, 2024)
- H.B. Fuller Company signs agreements to acquire Medifill Ltd. and GEM S.r.l. to expand its Medical Adhesive Technologies business (December 2, 2024)
Who to call at Celltrion, and when
When Celltrion changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Celltrion raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Celltrion, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Celltrion. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Celltrion makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired iQone Healthcare Switzerland?
iQone Healthcare Switzerland was acquired by Celltrion, based in Incheon. The deal was reported on November 14, 2024. Celltrion is privately held and operates in Manufacturing.
When did Celltrion acquire iQone Healthcare Switzerland?
Celltrion's acquisition of iQone Healthcare Switzerland was reported on November 14, 2024. Celltrion, a global biopharmaceutical leader, has announced the acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does iQone Healthcare Switzerland do?
iQone Healthcare Switzerland is an independent Swiss specialty pharma company focussing on the commercialisation of biosimilars, orphan drugs and oncology products. It is privately held, operating in Biotechnology, and is based in Versoix.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.